AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21366805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 20129385 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen‐LDL‐apheresis
Number of subjects: 200
Study 17507306 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide plus one of the new ritonavir‐boosted protease inhibitors (tipranavir or darunavir) and an optimised background treatment regimen
Number of subjects: 0
Study 17507306 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Number of subjects: 0
Study 15501375 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivated Stepped Care (MSC) with behavioral contingencies
Number of subjects: 127
Study 15501375 — intervention group
Group type: COMPARATOR
Intervention: Standard Stepped Care (SSC) without behavioral contingencies
Number of subjects: 127
Study 11470622 — intervention group
Group type: EXPERIMENTAL
Intervention: Pen-based interface
Number of subjects: 0
Study 11470622 — intervention group
Group type: COMPARATOR
Intervention: Keyboard interface
Number of subjects: 0
Study 10068730 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple regimen PAC (pantoprazole 40 mg bid, clarithromycin 500 mg tid, amoxicillin 1 g bid)
Number of subjects: 74
Study 10068730 — intervention group
Group type: COMPARATOR
Intervention: Dual regimen PC (pantoprazole, clarithromycin, placebo)
Number of subjects: 74
Study 7993327 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression of thoughts
Number of subjects: 0
Study 7993327 — intervention group
Group type: COMPARATOR
Intervention: Thinking about thoughts
Number of subjects: 0
Study 7993327 — intervention group
Group type: COMPARATOR
Intervention: Recording thoughts
Number of subjects: 0
Study 2178870 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam daily
Number of subjects: 24
Study 2178870 — intervention group
Group type: COMPARATOR
Intervention: 50 mg diclofenac twice daily
Number of subjects: 24
Study 2178870 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 24
Study 88710 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (narcotic) delivered in a demand analgesia (DA) system, dosage varied in response to patient-triggered apparatus.
Number of subjects: 34
Study 31006941 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Benefit Finding Scale for Parents (DBFS-P)
Number of subjects: 172
Study 27868359 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin add-on group (linagliptin 5 mg/day)
Number of subjects: 96
Study 27868359 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin group (1,500 mg/day)
Number of subjects: 96
Study 27868359 — intervention group
Group type: COMPARATOR
Intervention: Control group (metformin 750 mg/day)
Number of subjects: 96
Study 25891223 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft (gracilis and semitendinosus tendons)
Number of subjects: 102
Study 25891223 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid graft (γ‐irradiated tibialis anterior tendon allograft and semitendinosus tendon autograft)
Number of subjects: 102
Study 25891223 — intervention group
Group type: COMPARATOR
Intervention: γ‐irradiated allograft (tibialis anterior tendons)
Number of subjects: 102
Study 23830727 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive structured education programme (CSSEP)
Number of subjects: 430
Study 21312345 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-avoidance treatment (16 twice-weekly sessions of cognitive-behavioral therapy and exercise training)
Number of subjects: 0
Study 21312345 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-persistence treatment (16 twice-weekly sessions of cognitive-behavioral therapy and exercise training)
Number of subjects: 0
Study 21312345 — intervention group
Group type: COMPARATOR
Intervention: Pain-avoidance treatment
Number of subjects: 0
Study 21312345 — intervention group
Group type: COMPARATOR
Intervention: Pain-persistence treatment
Number of subjects: 0
Study 19058896 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic life support‐defibrillation (BLS‐D) training
Number of subjects: 52
Study 19058896 — intervention group
Group type: COMPARATOR
Intervention: No previous BLS‐D training with dispatcher assistance
Number of subjects: 52
Study 17366335 — intervention group
Group type: EXPERIMENTAL
Intervention: Persuasive educational mailing intervention
Number of subjects: 8499
Study 17366335 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 8499
Study 15583226 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 days of sleep restriction
Number of subjects: 12
Study 15583226 — intervention group
Group type: COMPARATOR
Intervention: 2 days of sleep extension
Number of subjects: 12
Study 11484963 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine at 25 mg/m2 weekly for at least eight weeks
Number of subjects: 47
Study 11484963 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Number of subjects: 47
Study 9552027 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP (etoposide, ifosfamide, and cisplatin)
Number of subjects: 304
Study 9552027 — intervention group
Group type: COMPARATOR
Intervention: BEP (bleomycin, etoposide, and cisplatin)
Number of subjects: 304
Study 7920274 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of one gram of Ambroxol in 500 ml of 0.9% saline daily for 5 days
Number of subjects: 20
Study 7920274 — intervention group
Group type: COMPARATOR
Intervention: Control group received infusions of 500 ml 0.9% saline at the same intervals
Number of subjects: 20
Study 2968248 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate PTCA after thrombolysis
Number of subjects: 533
Study 2968248 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis alone
Number of subjects: 533
Study 1093947 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy
Number of subjects: 100
Study 1093947 — intervention group
Group type: COMPARATOR
Intervention: Selective vagotomy with pyloroplasty
Number of subjects: 100
Study 31302020 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentari health education
Number of subjects: 64
Study 31302020 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 28612897 — intervention group
Group type: EXPERIMENTAL
Intervention: Italian version of the WHO questionnaire on Workplace Violence in the Health Sector
Number of subjects: 55
Study 25413366 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (AngII) infusion
Number of subjects: 60
Study 25413366 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH infusion
Number of subjects: 60
Study 25413366 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt diet
Number of subjects: 60
Study 25413366 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet
Number of subjects: 60
Study 23531317 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel Exhaust (DE) exposure
Number of subjects: 32
Study 23531317 — intervention group
Group type: COMPARATOR
Intervention: Filtered Air (FA) exposure
Number of subjects: 32
Study 21501479 — intervention group
Group type: EXPERIMENTAL
Intervention: Training programme for young cannabis users (CAN Stop)
Number of subjects: 0
Study 21501479 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 19352186 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoflex endotracheal tube for oral intubation
Number of subjects: 60
Study 19352186 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoflex endotracheal tube for nasal intubation
Number of subjects: 60
Study 19352186 — intervention group
Group type: COMPARATOR
Intervention: Conventional endotracheal tube with stylet for oral intubation
Number of subjects: 60
Study 19352186 — intervention group
Group type: COMPARATOR
Intervention: Conventional endotracheal tube for nasal intubation
Number of subjects: 60
Study 16756423 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg diazepam
Number of subjects: 18
Study 16756423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15536765 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol with high thujone concentration
Number of subjects: 25
Study 15536765 — intervention group
Group type: COMPARATOR
Intervention: Alcohol
Number of subjects: 25
Study 15536765 — intervention group
Group type: COMPARATOR
Intervention: Alcohol with low thujone concentration
Number of subjects: 25
Study 15536765 — intervention group
Group type: EXPERIMENTAL
Intervention: High thujone concentration
Number of subjects: 25
Study 10839290 — intervention group
Group type: EXPERIMENTAL
Intervention: BW12C and MMC
Number of subjects: 17
Study 9405961 — intervention group
Group type: EXPERIMENTAL
Intervention: tianeptine (37.5 mg/day)
Number of subjects: 556
Study 9405961 — intervention group
Group type: EXPERIMENTAL
Intervention: imipramine (150 mg/day)
Number of subjects: 556
Study 9405961 — intervention group
Group type: EXPERIMENTAL
Intervention: tianeptine (75 mg/day)
Number of subjects: 556
Study 9405961 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 556
Study 8403764 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus chasing technique
Number of subjects: 116
Study 8403764 — intervention group
Group type: COMPARATOR
Intervention: Conventional stepped technique
Number of subjects: 116
Study 2876005 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201-995 (50 micrograms sc bolus before meals)
Number of subjects: 6
Study 2876005 — intervention group
Group type: COMPARATOR
Intervention: Control (standardized mixed meals without SMS 201-995)
Number of subjects: 6
Study 29753704 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy/auriculotherapy group (n = 11)
Number of subjects: 22
Study 29753704 — intervention group
Group type: COMPARATOR
Intervention: Kinesiotherapy group (n = 11)
Number of subjects: 22
Study 27315293 — intervention group
Group type: EXPERIMENTAL
Intervention: INTACS-SK (Intacs, Addition Technology, Inc.)
Number of subjects: 69
Study 27315293 — intervention group
Group type: EXPERIMENTAL
Intervention: KeraRing SI6 (Mediaphacos Ltda.)
Number of subjects: 69
Study 24469436 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophageal cooling with ice water (5 mL injected prior to RF energy delivery)
Number of subjects: 100
Study 24469436 — intervention group
Group type: COMPARATOR
Intervention: Control group (oesophageal cooling not applied)
Number of subjects: 100
Study 24469436 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophageal cooling with ice water
Number of subjects: 100
Study 24469436 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 22279570 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating Angiopoietin-2 (Ang-2) levels during active AAV
Number of subjects: 162
Study 22279570 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating Angiopoietin-2 (Ang-2) levels during remission
Number of subjects: 162
Study 22279570 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Ang-2 with BVAS/WG score
Number of subjects: 162
Study 22279570 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Ang-2 with markers of systemic inflammation
Number of subjects: 162
Study 22279570 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Ang-2 with renal function
Number of subjects: 162
Study 22279570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ang-2 levels in patients with glomerulonephritis
Number of subjects: 162
Study 22279570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ang-2 levels in newly diagnosed AAV patients
Number of subjects: 162
Study 22279570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ang-2 levels in patients recently started on treatment
Number of subjects: 162
Study 22279570 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive value of Ang-2 levels during active disease
Number of subjects: 162
Study 22279570 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive value of Ang-2 levels in remission
Number of subjects: 162
Study 19684105 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy
Number of subjects: 380
Study 19013285 — intervention group
Group type: EXPERIMENTAL
Intervention: Strawberry supplementation (454 g/d, 112 kcal)
Number of subjects: 28
Study 19013285 — intervention group
Group type: COMPARATOR
Intervention: Oat bran bread (control, 65 g/d, 112 kcal, approximately 2 g beta-glucan)
Number of subjects: 28
Study 19013285 — intervention group
Group type: EXPERIMENTAL
Intervention: Strawberry supplementation
Number of subjects: 28
Study 15809481 — intervention group
Group type: COMPARATOR
Intervention: Setup A (standard PET head holder with no support at the sides)
Number of subjects: 51
Study 15809481 — intervention group
Group type: EXPERIMENTAL
Intervention: Setup B (special head holder fitted with a subject-specific mold from construction foam)
Number of subjects: 51
Study 15809481 — intervention group
Group type: EXPERIMENTAL
Intervention: Setup C (vacuum-lock bag)
Number of subjects: 51
Study 15809481 — intervention group
Group type: EXPERIMENTAL
Intervention: Setup D (special head holder fitted with a vacuum-lock bag)
Number of subjects: 51
Study 15809481 — intervention group
Group type: EXPERIMENTAL
Intervention: Setup C in clinical PET/CT
Number of subjects: 51
Study 12867883 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE-1
Number of subjects: 123
Study 12867883 — intervention group
Group type: COMPARATOR
Intervention: pentoxyfillin-buflomedil
Number of subjects: 123
Study 9862876 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy for chronic hepatitis C (24 weeks duration)
Number of subjects: 642
Study 9862876 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained viral response to interferon therapy (n = 41)
Number of subjects: 642
Study 9862876 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained biochemical responses to interferon therapy
Number of subjects: 642
Study 9862876 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 750)
Number of subjects: 642
Study 8571994 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises for 3 months
Number of subjects: 71
Study 8571994 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises for 3 months (completed treatment)
Number of subjects: 71
Study 8571994 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle exercises with audiotape
Number of subjects: 71
Study 8571994 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises (6 months follow-up)
Number of subjects: 71
Study 1677698 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% aqueous chlorhexidine
Number of subjects: 668
Study 1677698 — intervention group
Group type: COMPARATOR
Intervention: 70% alcohol
Number of subjects: 668
Study 1677698 — intervention group
Group type: COMPARATOR
Intervention: 10% povidone-iodine
Number of subjects: 668
Study 1677698 — intervention group
Group type: COMPARATOR
Intervention: Infusion-related bacteraemias
Number of subjects: 668
Study 6837487 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (jogging for 20 to 50 min/day for 6 weeks)
Number of subjects: 12
Study 6837487 — intervention group
Group type: COMPARATOR
Intervention: Sedentary living (no exercise for 6 weeks)
Number of subjects: 12
Study 31039786 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help app for one month
Number of subjects: 234
Study 31039786 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational reading material (brochure)
Number of subjects: 234
Study 29367116 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) treatment
Number of subjects: 110
Study 29367116 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent reinforcement (NR)
Number of subjects: 110
Study 29367116 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased drinking during the Initial Phase
Number of subjects: 110
Study 26996450 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative physiotherapy for six weeks
Number of subjects: 50
Study 26996450 — intervention group
Group type: COMPARATOR
Intervention: Nonphysiotherapy group
Number of subjects: 50
Study 26996450 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 24628830 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 30
Study 24628830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 30
Study 22094531 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion
Number of subjects: 21
Study 22094531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 21119316 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Number of subjects: 10
Study 21119316 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10
Study 17966977 — intervention group
Group type: COMPARATOR
Intervention: Pomegranate ellagitannin-enriched polyphenol extract (POMx) - 710 mg or 1420 mg per day
Number of subjects: 64
Study 17966977 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate ellagitannin-enriched polyphenol extract (POMx) - 1000 mg per day
Number of subjects: 64
Study 14981375 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (two 2-g doses, 48 hours apart)
Number of subjects: 1341
Study 14981375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1341
Study 12411539 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate clamp (LC) procedure with exogenous lactate infusion clamped at approximately 4 mM during exercise at 55% V(O2,peak)
Number of subjects: 0
Study 9820381 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. plus amoxicillin 1 g b.i.d. plus clarithromycin 500 mg b.i.d. (OAC)
Number of subjects: 507
Study 9820381 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus amoxicillin 1 g b.i.d. plus clarithromycin 500 mg b.i.d. (AC)
Number of subjects: 507
Study 7644398 — intervention group
Group type: EXPERIMENTAL
Intervention: Antituberculosis treatment regimen including pyrazinamide, isoniazid, and rifampicin
Number of subjects: 60
Study 7644398 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 2755692 — intervention group
Group type: EXPERIMENTAL
Intervention: Roth's sealer
Number of subjects: 60
Study 2755692 — intervention group
Group type: EXPERIMENTAL
Intervention: AH26
Number of subjects: 60
Study 2755692 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealapex
Number of subjects: 60
Study 2755692 — intervention group
Group type: EXPERIMENTAL
Intervention: CRCS
Number of subjects: 60
Study 2755692 — intervention group
Group type: EXPERIMENTAL
Intervention: Nogenol sealer
Number of subjects: 60
Study 2755692 — intervention group
Group type: COMPARATOR
Intervention: Control (no sealer)
Number of subjects: 60
Study 806396 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% solution of sodium cromoglycate
Number of subjects: 19
Study 806396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30343388 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA2G16 SNPs (rs11600655, rs3809072, rs3809073, rs640908, rs66475048)
Number of subjects: 498
Study 30343388 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotypes (CTC and GGA) of rs11600655, rs3809073, and rs3809072
Number of subjects: 498
Study 30343388 — intervention group
Group type: EXPERIMENTAL
Intervention: rs11600655 polymorphism
Number of subjects: 498
Study 30343388 — intervention group
Group type: EXPERIMENTAL
Intervention: rs3809073 and rs3809072
Number of subjects: 498
Study 30343388 — intervention group
Group type: EXPERIMENTAL
Intervention: rs11600655 CC, rs640908 CT, and rs66475048 GA genotypes
Number of subjects: 498
Study 27218216 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGF‐1
Number of subjects: 108
Study 27218216 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum TNF‐alpha
Number of subjects: 108
Study 27218216 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum VEGF165
Number of subjects: 108
Study 27218216 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 108
Study 25138123 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training program (50‐60 min aerobic, strengthening and stretching exercise, 3 days a week, for 12 weeks)
Number of subjects: 37
Study 25138123 — intervention group
Group type: COMPARATOR
Intervention: No training program at all (control group)
Number of subjects: 37
Study 23246533 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 0
Study 23246533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21419674 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric low-fat diet
Number of subjects: 24
Study 18469662 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% lidocaine solution (10 mL of 1% lidocaine in 1 L saline)
Number of subjects: 100
Study 18469662 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 100
Study 16546756 — intervention group
Group type: COMPARATOR
Intervention: Caregivers of ALS patients rated premorbid personality traits using the NEO-Personality Inventory.
Number of subjects: 0
Study 11323346 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapacuronium (RAP) 1.5 mg/kg
Number of subjects: 3
Study 11323346 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (VEC) 0.1 mg/kg
Number of subjects: 3
Study 11323346 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (SUC) 1 mg/kg
Number of subjects: 3
Study 11323346 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (VEC) 0.025 mg/kg (0.5 x ED(95)) after RAP
Number of subjects: 3
Study 11323346 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (VEC) 0.025 mg/kg (0.5 x ED(95)) after VEC
Number of subjects: 3
Study 11323346 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (VEC) 0.025 mg/kg (0.5 x ED(95)) after SUC
Number of subjects: 3
Study 11323346 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (VEC) after RAP
Number of subjects: 3
Study 11323346 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (VEC) after VEC
Number of subjects: 3
Study 11323346 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (VEC) after SUC
Number of subjects: 3
Study 9182212 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab with low-dose heparin (initial bolus of 70 U per kilogram)
Number of subjects: 2792